SCHEMBL269764

SCHEMBL269764

Oc1[c]cc2ccccc2n1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.42
MAPT P10636 5/20 0.42
HPGD P15428 2/20 0.42
GLA P06280 2/20 0.42
ACHE P22303 2/20 0.42
KDM4E B2RXH2 5/20 0.41
GAA P10253 2/20 0.41
STAT3 P40763 1/20 0.41
AR P10275 1/20 0.38
NCF1 P14598 2/20 0.37
CYP1A2 P05177 2/20 0.37
NOS2 P35228 1/20 0.37
BACE1 P56817 1/20 0.37
CA12 O43570 1/20 0.37
CA9 Q16790 1/20 0.37
MGAM O43451 1/20 0.36
NQO2 P16083 1/20 0.36
RAB9A P51151 3/20 0.34
KMT2A Q03164 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2989781 0.75 CYP1A2 (0.47) ALDH1A1MAPTHPGDKDM4ECYP1A2
SCHEMBL466391 0.73 ALDH1A1 (0.42) ALDH1A1MAPTHPGDGLAACHE
SCHEMBL4717309 0.73 NCF1 (0.46) ALDH1A1MAPTHPGDGLAACHE
SCHEMBL529257 0.73 ALDH1A1 (0.42) ALDH1A1MAPTHPGDGLAACHE
SCHEMBL19359 0.73 CYP1A2 (0.46) ALDH1A1MAPTHPGDGLAACHE
SCHEMBL12504960 0.72 AR (0.51) ALDH1A1MAPTHPGDGLAKDM4E
SCHEMBL2992161 0.72 CYP1A2 (0.50) ALDH1A1MAPTKDM4EGAACYP1A2
SCHEMBL9602129 0.71 MGAM (0.48) ALDH1A1MAPTHPGDGLAACHE
SCHEMBL5777774 0.70 IKBKB (0.46) ALDH1A1MAPTHPGDGLAACHE
SCHEMBL2996550 0.70 PDE10A (0.40) ALDH1A1MAPTHPGDGLAACHE

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 269 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10077261-B2 Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer JANSSEN PHARMACEUTICA NV (BE) 2018-09-18 US claimed
US-9732227-B2 Modified colorants and inkjet ink compositions comprising modified colorants CABOT CORPORATION (US) 2017-08-15 US claimed
EP-2892892-B1 IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SYNTHASE (FASN) INHIBITORS FOR THE TREATMENT OF CANCER JANSSEN PHARMACEUTICA NV (BE) 2017-05-31 EP claimed
US-20160075880-A1 Modified Colorants and Inkjet Ink Compositions Comprising Modified Colorants CABOT CORPORATION 2016-03-17 US claimed
US-20160002219-A1 IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER JANSSEN PHARMACEUTICA NV (BE) 2016-01-07 US claimed
US-9090593-B2 Bicyclic compounds as Pim inhibitors AMGEN INC. (US) 2015-07-28 US claimed
EP-2892892-A1 IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR!THE TREATMENT OF CANCER Janssen Pharmaceutica N.V. (BE) 2015-07-15 EP claimed
US-20150099730-A1 IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER JANSSEN PHARMACEUTICA, NV (BE) 2015-04-09 US claimed
WO-2014039769-A1 IMIDAZOLIN-5-ONE DERIVATIVES USEFUL AS FATTY ACID SNTHASE (FASN) INHIBITORS FOR|THE TREATMENT OF CANCER JANSSEN PHARMACEUTICA NV (BE) 2014-03-13 WO claimed
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS AMGEN INC. (US) 2014-01-30 US claimed
US-5338846-A Process for preparing aryl piperazinyl-heterocyclic compounds with a piperazine salt PFIZER INC. (US) 1994-08-16 US claimed
EP-0584903-A1 Process for preparing aryl piperazinyl-heterocyclic compounds PFIZER INC. (US) 1994-03-02 EP claimed
US-5206366-A Process for preparing aryl piperazinyl-heterocyclic compounds PFIZER INC. (US) 1993-04-27 US claimed
EP-0281309-B1 PIPERAZINYL-HETEROCYCLIC COMPOUNDS PFIZER INC. (US) 1991-12-27 EP claimed
EP-0229947-B1 NOVEL CRYSTALLINE SALTS OF ARYLOXY-PROPANOLAMINES, THEIR PREPARATION AND THEIR USE RORER INTERNATIONAL (OVERSEAS) INC. (US) 1991-03-13 EP claimed
US-4883795-A Piperazinyl-heterocyclic compounds PFIZER INC. (US) 1989-11-28 US claimed
EP-0159962-B1 FIBRE-REACTIVE CHROMIUM OR COBALT COMPLEXES, THEIR PREPARATION AND THEIR USE CIBA-GEIGY AG (CH) 1989-02-08 EP claimed
EP-0281309-A1 Piperazinyl-heterocyclic compounds PFIZER INC. (US) 1988-09-07 EP claimed
US-4680385-A Metal dye complexes containing an azo or azomethine dye and a colorless ligand with the C═N--N═C group CIBA-GEIGY CORPORATION (US) 1987-07-14 US claimed
US-4678851-A FIBER-RACTIVE CIBA-GEIGY CORPORATION (US) 1987-07-07 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150099730-A1 IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER FASN, PLIN1, FABP1 ALDH1A1 197/4885MAPT 4730/4885HPGD 1499/4885
US-10077261-B2 Imidazolin-5-one derivative useful as FASN inhibitors for the treatment of cancer FASN, PLIN1, FABP1 ALDH1A1 197/4885MAPT 4730/4885HPGD 1499/4885
US-20160002219-A1 IMIDAZOLIN-5-ONE DERIVATIVE USEFUL AS FASN INHIBITORS FOR THE TREATMENT OF CANCER FASN, PLIN1, FABP1 ALDH1A1 197/4885MAPT 4730/4885HPGD 1499/4885
US-20140031360-A1 BICYCLIC COMPOUNDS AS PIM INHIBITORS PIM1, PIM2, PIM3 ALDH1A1 502/4885MAPT 3618/4885HPGD 2221/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.